Israeli biotech Nasus has developed the Taffix anti-viral nasal spray. It creates a thin gel over the nasal mucosa, blocking viruses for 4-5 hours. In recent tests, Taffix reduced Covid-19 infections from 10% down to 2.4%. Taffix is marketed in Europe and available at SuperPharm in Israel.

https://www.nasuspharma.com/nasus-pharma-announces-first-clinical-data-demonstrating-efficacy-of-taffixtm-intranasal-antiviral-protection-against-sars-cov-2-in/

https://www.nasuspharma.com/taffix/